165 related articles for article (PubMed ID: 20601094)
1. Ezetimibe as a potential treatment for non-alcoholic fatty liver disease: is the intestine a modulator of hepatic insulin sensitivity and hepatic fat accumulation?
Ahmed MH; Byrne CD
Drug Discov Today; 2010 Aug; 15(15-16):590-5. PubMed ID: 20601094
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of intestinal cholesterol absorption by ezetimibe is a novel therapeutic target for fatty liver.
Yamagishi S; Nakamura K; Matsui T; Sato T; Takeuchi M
Med Hypotheses; 2006; 66(4):844-6. PubMed ID: 16188393
[TBL] [Abstract][Full Text] [Related]
3. Potential therapeutic uses for ezetimibe beyond lowering LDL-c to decrease cardiovascular events.
Ahmed MH; Byrne CD
Diabetes Obes Metab; 2010 Nov; 12(11):958-66. PubMed ID: 20880342
[TBL] [Abstract][Full Text] [Related]
4. Ezetimibe improves high fat and cholesterol diet-induced non-alcoholic fatty liver disease in mice.
Zheng S; Hoos L; Cook J; Tetzloff G; Davis H; van Heek M; Hwa JJ
Eur J Pharmacol; 2008 Apr; 584(1):118-24. PubMed ID: 18329014
[TBL] [Abstract][Full Text] [Related]
5. Ezetimibe improves liver steatosis and insulin resistance in obese rat model of metabolic syndrome.
Deushi M; Nomura M; Kawakami A; Haraguchi M; Ito M; Okazaki M; Ishii H; Yoshida M
FEBS Lett; 2007 Dec; 581(29):5664-70. PubMed ID: 18022391
[TBL] [Abstract][Full Text] [Related]
6. Ezetimibe decreases SREBP-1c expression in liver and reverses hepatic insulin resistance in mice fed a high-fat diet.
Muraoka T; Aoki K; Iwasaki T; Shinoda K; Nakamura A; Aburatani H; Mori S; Tokuyama K; Kubota N; Kadowaki T; Terauchi Y
Metabolism; 2011 May; 60(5):617-28. PubMed ID: 20673929
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of hepatic Niemann-Pick C1-like 1 improves hepatic insulin resistance.
Nomura M; Ishii H; Kawakami A; Yoshida M
Am J Physiol Endocrinol Metab; 2009 Nov; 297(5):E1030-8. PubMed ID: 19654286
[TBL] [Abstract][Full Text] [Related]
8. Novel role of NPC1L1 in the regulation of hepatic metabolism: potential contribution of ezetimibe in NAFLD/NASH treatment.
Yoshida M
Curr Vasc Pharmacol; 2011 Jan; 9(1):121-3. PubMed ID: 21044016
[TBL] [Abstract][Full Text] [Related]
9. The Niemann-Pick C1 like 1 (NPC1L1) inhibitor ezetimibe improves metabolic disease via decreased liver X receptor (LXR) activity in liver of obese male mice.
Sugizaki T; Watanabe M; Horai Y; Kaneko-Iwasaki N; Arita E; Miyazaki T; Morimoto K; Honda A; Irie J; Itoh H
Endocrinology; 2014 Aug; 155(8):2810-9. PubMed ID: 24773344
[TBL] [Abstract][Full Text] [Related]
10. Long-term combination therapy of ezetimibe and acarbose for non-alcoholic fatty liver disease.
Nozaki Y; Fujita K; Yoneda M; Wada K; Shinohara Y; Takahashi H; Kirikoshi H; Inamori M; Kubota K; Saito S; Mizoue T; Masaki N; Nagashima Y; Terauchi Y; Nakajima A
J Hepatol; 2009 Sep; 51(3):548-56. PubMed ID: 19596472
[TBL] [Abstract][Full Text] [Related]
11. NPC1L1 inhibitor ezetimibe is a reliable therapeutic agent for non-obese patients with nonalcoholic fatty liver disease.
Enjoji M; Machida K; Kohjima M; Kato M; Kotoh K; Matsunaga K; Nakashima M; Nakamuta M
Lipids Health Dis; 2010 Mar; 9():29. PubMed ID: 20222991
[TBL] [Abstract][Full Text] [Related]
12. Hepatic Niemann-Pick C1-like 1.
Pramfalk C; Jiang ZY; Parini P
Curr Opin Lipidol; 2011 Jun; 22(3):225-30. PubMed ID: 21494140
[TBL] [Abstract][Full Text] [Related]
13. Ezetimibe ameliorates cardiovascular complications and hepatic steatosis in obese and type 2 diabetic db/db mice.
Fukuda M; Nakamura T; Kataoka K; Nako H; Tokutomi Y; Dong YF; Yasuda O; Ogawa H; Kim-Mitsuyama S
J Pharmacol Exp Ther; 2010 Oct; 335(1):70-5. PubMed ID: 20651026
[TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of combined ezetimibe/simvastatin treatment and simvastatin monotherapy in patients with non-alcoholic fatty liver disease.
Abel T; Fehér J; Dinya E; Eldin MG; Kovács A
Med Sci Monit; 2009 Dec; 15(12):MS6-11. PubMed ID: 19946244
[TBL] [Abstract][Full Text] [Related]
15. The cholesterol absorption inhibitor ezetimibe acts by blocking the sterol-induced internalization of NPC1L1.
Ge L; Wang J; Qi W; Miao HH; Cao J; Qu YX; Li BL; Song BL
Cell Metab; 2008 Jun; 7(6):508-19. PubMed ID: 18522832
[TBL] [Abstract][Full Text] [Related]
16. Ezetimibe prevents cholesterol gallstone formation in mice.
Zúñiga S; Molina H; Azocar L; Amigo L; Nervi F; Pimentel F; Jarufe N; Arrese M; Lammert F; Miquel JF
Liver Int; 2008 Aug; 28(7):935-47. PubMed ID: 18783541
[TBL] [Abstract][Full Text] [Related]
17. Cardiovascular Risk Reduction in Patients with Nonalcoholic Fatty Liver Disease: The Potential Role of Ezetimibe.
Simon TG; Corey KE; Chung RT; Giugliano R
Dig Dis Sci; 2016 Dec; 61(12):3425-3435. PubMed ID: 27714510
[TBL] [Abstract][Full Text] [Related]
18. In vivo responsiveness to ezetimibe correlates with niemann-pick C1 like-1 (NPC1L1) binding affinity: Comparison of multiple species NPC1L1 orthologs.
Hawes BE; O'neill KA; Yao X; Crona JH; Davis HR; Graziano MP; Altmann SW
Mol Pharmacol; 2007 Jan; 71(1):19-29. PubMed ID: 17005902
[TBL] [Abstract][Full Text] [Related]
19. Effect of insulin-sensitizing agents in combination with ezetimibe, and valsartan in rats with non-alcoholic fatty liver disease.
Assy N; Grozovski M; Bersudsky I; Szvalb S; Hussein O
World J Gastroenterol; 2006 Jul; 12(27):4369-76. PubMed ID: 16865780
[TBL] [Abstract][Full Text] [Related]
20. Ezetimibe reduces fatty acid quantity in liver and decreased inflammatory cell infiltration and improved NASH in medaka model.
Oishi T; Terai S; Kuwashiro S; Fujisawa K; Matsumoto T; Nishina H; Sakaida I
Biochem Biophys Res Commun; 2012 May; 422(1):22-7. PubMed ID: 22554516
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]